Publique en esta revista
Información de la revista
Vol. 14. Núm. 1.
Páginas 1-4 (Enero - Marzo 1978)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 14. Núm. 1.
Páginas 1-4 (Enero - Marzo 1978)
DOI: 10.1016/S0300-2896(15)32635-1
Acceso a texto completo
La inmunidad celular y la respuesta a la quimioterapia en pacientes afectos de cancer de pulmon metastasico
Cellular immunity and response to chemotherapy of patients affected with metastatic lung cancer
Visitas
1017
E. Simó-Camps*, F. Manresa**
* Jefe del Servicio de Medicina Interna. Residencia Virgen de la Cinta. Tortosa. Tarragona.
** Jefe clínico del Instituto de Neumologia Clínica Ntra. Sra. de la Merced. Barcelona
J.M.a Vich
Este artículo ha recibido
1017
Visitas
Información del artículo
Resumen

Se estudian 138 pacientes afectos de carcinoma pulmonar metastásico en su aspecto inmunológico.

Los estudios in vitro e in vivo de la inmunidad celular ponen de manifiesto que existe correlación entre una buena respuesta a la quimioterapia y la existencia de una respuesta inmune positiva frente a los parámetros estudiados en este grupo de enfermos. El 84,3% de enfermos que mejoraron clínicamente tenían respuestas inmunes positivas, mientras que únicamente 12,7% con respuestas inmunológicas favorables remitieron clínicamente.

Summary

The authors study the cases of 138 patients affected with metastasic lung cáncer in their immunological aspects.

Studies in vitro and in vivo of the cellular immunity show that a correlation exists between a good response to chemotherapy and the existence of a positive immune respone to the parameters studied in this group of patients. Of the patients that improved clinically, 84.3% had positive immune responses, while only 12.7% with favorable immunological responses showed clinical remission.

El Texto completo está disponible en PDF
Bibliografia
[1.]
C.M. Southam, A.E. Moore, C.P. Rhoads.
Homotransplantation of human cellines.
Science, 125 (1957), pp. 158
[2.]
F.R. Eilber, D.L. Morton.
Impaired immunologic reactivity and recurrence following cancer surgery.
Cancer, 2 (1970), pp. 362
[3.]
M.J. Krand, G. Manskoff, C. Brandrup, A.M. Morton.
Immunologic alterations in bronchogenic cancer.
Cancer, 4 (1968), pp. 623
[4.]
A.C. Levin, E.F. Mcdonough, D.G. Miller, C.M. Southam.
Delayed hypersensitivity response to DNFB in sick and healthy persons.
Ann. N.Y. Acad. Sci., 120 (1964), pp. 400
[5.]
L.A.M.B.D. Pilney, W.D. Kelley, R.A. Good.
A comparative study of the incidence of energy in patients with carcinoma leukemia. Hodgkin's disease, and other lymphomas.
J. Immunol., 89 (1962), pp. 555
[6.]
D.S.P. Cuadrado.
Blastogénesis y cáncer humano: Depresión del índice blastogénico en los enfermos cancerosos: Rev.
Clín. Esp., 103 (1966), pp. 13
[7.]
W.J. Catalona, W.F. Sample, P.B. Chretien.
Lymphocyte reactivity in cancer patients. Correlation with tumor histology and clinical stage.
Cancer, 31 (1973), pp. 65
[8.]
J. Ducos, J. Migueras, P. Colombies, A. Kessous, N. Poujouluet.
Lymphocyte response to PHA in patients with lung cancer.
Lancet, 1 (1970), pp. 1111
[9.]
P.B. Garrioch, R.A. Good, A.A. Gatti.
Lymphocyte response to PHA in patients with nonlymphoid tumors.
Lancet, 1 (1970), pp. 618
[10.]
E.M. Hersh, J.J. Oppenheim.
Impaired in vitro lymphocyte transformation in Hodgkin's disease.
New. Engl. J. Med., 273 (1965), pp. 1003
[11.]
R.M. Sutherland, W.R. Inch, T.H. Mcc Edie.
Phytohemagglutinin (PHA-indiced transformation of lymphocytes from patients with cancer.
Cancer, 27 (1971), pp. 574
[12.]
O.P. Sharma, D.G. James, R.A. Fox.
A correlation of in vivo delayed type hypersensitivity with in vitro lymphocyte transformation in sarcoidosis.
Chest, 60 (1971), pp. 35
[13.]
S. Trubowits, B. Masek, A. Del Rosario.
Lymphocyte response to phytohemagglutinin in Hodgkin's disease, lyrnphatic leukemia and lymphosarcoma.
Cancer, 19 (1965), pp. 2019
[14.]
P. Twomey, W.J. Catalona, P.B. Chretien.
Cellular immunity in cured cancer patients.
Cancer, 33 (1974), pp. 435
[15.]
M.G. Wittaker, K. Rees, C.G. Clark.
Reduced lymphocyte transformation in breast cancer.
Lancet, 1 (1977), pp. 892
[16.]
A.C. Aisenberg.
Studies on delayed hypersensitivity in Hodgkin's disease.
J. Clin. Invest., 41 (1971), pp. 1964
[17.]
A.C. Aisenberg.
Lymphocytopenia in Hodgkin's disease.
Blood, 25 (1965), pp. 1037
[18.]
J.W. Berg.
The incidence of mutiple primary cancer. Development of further cancers in patients with lymphomas and myelomas.
J. Nat. Cancer Inst., 38 (1967), pp. 741
[19.]
BROWN, R.S., HAYNES, H.A., FOLEY, H.T., GODWIN, H.A., BERNARD, C.W., y CARBONE, P.B. Hodgkin's disease immunologic, clinical and histologic features of 50 untreated patients. Ann. Inter. Med., 67: 291, 1267.
[20.]
G.A. Hyman.
Increased incidense of neoplasia, in association with chronic lymphocytic leukemia.
Scand. J. Haemat, 6 (1969), pp. 99
[21.]
D. Lamb, F. Pilney, W.D. Kelley, R.A. Good.
A comparative study of the incidence of energy in patients with carcinoma, leukemia, Hodgkin's disease, and other lymphomas.
J. Immunol., 89 (1962), pp. 555
[22.]
C.G. Moertel, R.H. Hagerdorn, I. Aisrl.
Leukemia and lymphoma, and primary coexistent malignant lesions.
Review of literature and study of 120 ca. Blood, 12 (1957), pp. 788
[23.]
A.D. Rubin, K. Haveman, W. Dameshek.
Studies in chronic lymphocytic Further Studies of the proliferative abnormality of the blood lymphocyte.
Blood, 33 (1969), pp. 313
[24.]
W.J. Catalona, P.B. Chretien.
Abnormalities of quantitative dinitro chlororobenzene sensitización in cancer patients: Correlation with tumor stage and histology.
Cancer, 31 (1973), pp. 353
[25.]
W.J. Catalona, W.F. Sample, P.B. Chretien.
Lymphocyte reactivity in cancer patients. Correlation with tumor histology and clinical stage.
Cancer, 31 (1973), pp. 65
[26.]
R.C. Chakravorty, H.P. Curuchet, F.S. Copolla, Ch Park, W.K. Blayloch, W. Lawrence Jr..
: The delayed hypersensitivity reaction in the cancer patients: Observations on sensitización by DNCB.
Suraery, 73 (1973), pp. 730
[27.]
D.L. Morton, E.C. Holmes, R.F. Eilber, W.C. Wood.
Immunological aspects of neoplasia: A rational basis forimmunotherapy.
Ann. Int. Med., 74 (1971), pp. 589
[28.]
H.S. Nelson.
Delayed hypersensitivity in cancer patients. Cutaneous and in vitro lymphocyte response to specific antigens.
J. Nat. Cancer Inst., 42 (1969), pp. 765
[29.]
B. Serrou, L. Solasol, S. Meis, H. Pujol, Cl. Romieu.
Aspects actuels de l’mmunologie et de l’immunotherapy des cancer chez l’homme.
J. Méd. Montp., 4 (1972), pp. 171
[30.]
A.C. Solowey, F.T. Rapaport.
Immunologic response in cancer patients.
Surg. Gynecol. Obstet., 121 (1965), pp. 756
[31.]
P.L. Twomey, W.J. Catalona, P.B. Chretien.
Cellular immunity in cured cancer patients.
Cancer, 33 (1974), pp. 435
[32.]
A.M. Anthony, G.H. Templeman, K.E. Madsen, M.K. Mason.
The pronostic significance of DHS skin tests in patients with carcinoma of bronchus.
Cancer, 34 (1974), pp. 1091
[33.]
A. Brugarolas, H. Takita.
Immunologic status in lung cancer.
Chest, 64 (1973), pp. 427
[34.]
A. Brugarolas, H. Han Takita, J. Minowada.
Immunologic assays in lung cancer.
N.Y. State J. Med., 73 (1973), pp. 747
[35.]
M. Silk.
Eflect of plasma from patients with carcinoma on in vitro lymphocyte transformation.
Cancer, 27 (1967), pp. 2088
[36.]
K. Israel, A. Bouvrain, J. Crossdecam, M. Mujica.
Contribution á l’ètude des phenomenes d’immunite cellular chez les cancereux pulmonaires avant traitment paliatif o chimrgical.
Poum. Cæur, 3 (1968), pp. 339
[37.]
E.M. Hersh, P.M. Luris, H. Takita, R. Ritis, M. Zelen.
Immunocompetance and prognosis in lung cancer.
Amer. Ass. Cancer Res., 67 (1976), pp. 230
[38.]
M.K. Micksche.
In vivo and in vitro hipersensitivity reactions in pacients with bronchogenic carcinoma.
Abstracts. International Cancer Congress, XI (1974), pp. 108
[39.]
J.C. Rees, J.L. Rossio, E. Wilson, J.P. Milton, C.D. Matthew.
Cellular immunity in neoplasia. Antigen and mitogen responses in patients with bronchogenic carcinoma.
Cancer, 36 (1975), pp. 2010
[40.]
R.L. Gross, A. Latty, E.A. Williams, P.M. Newberne.
Abnormal spontaneous rosette formation and rosette inhibition in lung carcinoma.
New Engl. J. Med., 292 (1975), pp. 439
[41.]
T. Hant, H. Takita.
Immunologic impairment in bronchogenic carcinoma: A study of lymphocyte response to Phytomemagglutinin.
Cancer, 30 (1972), pp. 616
[42.]
R.E. Ritts Jr., D.T. Carr.
Cellular immune competence in stage III bronchogenic carcinoma.
Abstracts, XI International Cancer Congress, 2 (1974), pp. 110
[43.]
S.A. Wells, J.F. Burdick, W.L. Joseph, C.L. Christiansens, W.G. Wolf, P.C. Adkins.
Delayed cutaneous hypersensitivity reactions to tumor cell antigens and to non specific antigens. Pronostic significance in patients with lung cancer.
Thor. Card. Surg., 66 (1973), pp. 557
[44.]
W.J. Catalona, P.T. Taylor, A.S. Raboson, P.B. Chretien.
A method for D.N.C.B. contact sensibilazation. A clinicopathology study.
New England J. Med., 286 (1972), pp. 399
[45.]
J.M. Moragas, A. Anguera.
Indice de transformación blástica de los linfocitos en las farmacodermias.
Rev. Clin. Esp., 124 (1972), pp. 3
[46.]
J. Wybran, H.H. Fudenberg.
Rosette formation, a test for cellular immunity.
Trans. Ass. Amer. Phys., 84 (1971), pp. 239
[47.]
J. Wybran, H.H. Fundenberg.
Thymus-derived rosette-forminf cells.
New Engl. J. Med., 288 (1973), pp. 710
[48.]
A.M. Anthony, G.H. Templeman, K.E. Madsen, M.K. Mason.
The pronostic significance of DHS skin tests in patients with carcinoma of bronchus.
Cancer, 34 (1974), pp. 1.091
[49.]
L.A. Dellon, Cl. Potyin, P.B. Chretien.
Thymus-dependent lymphocyte levels in bronchogenic carcinoma: Correlation with histology, clinical stage and clinical case after surgical treatment.
Cancer, 35 (1975), pp. 387
Copyright © 1978. Sociedad Española de Neumología y Cirugía Torácica
Idiomas
Archivos de Bronconeumología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.